MX2022003018A - Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. - Google Patents

Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.

Info

Publication number
MX2022003018A
MX2022003018A MX2022003018A MX2022003018A MX2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A
Authority
MX
Mexico
Prior art keywords
treating narcolepsy
tak
compound
methyl
subject
Prior art date
Application number
MX2022003018A
Other languages
English (en)
Inventor
Deborah Hartman
Rebecca Evans
Helene Faessel
Shinichiro Tanaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022003018A publication Critical patent/MX2022003018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para tratar la narcolepsia tipo 1 en un sujeto que lo necesite, que comprende administrar al sujeto una cantidad efectiva de 3-((metilsulfonil)amino)-2- (((4-fenilciclohexil)oxi)metil)piperidina-1-carboxilato de metilo (Compuesto (I)), o una sal del mismo, en donde la concentración plasmática del Compuesto (I) es de aproximadamente 5.04 ng/mL o más durante aproximadamente 1 hora o más. También se describen composiciones para tratar la narcolepsia tipo 1 que comprenden el Compuesto (I).
MX2022003018A 2019-09-13 2020-09-12 Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. MX2022003018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US202063031686P 2020-05-29 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
MX2022003018A true MX2022003018A (es) 2022-06-14

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003018A MX2022003018A (es) 2019-09-13 2020-09-12 Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.

Country Status (11)

Country Link
US (1) US20220339143A1 (es)
EP (1) EP4028004A1 (es)
JP (1) JP2022547711A (es)
KR (1) KR20220062012A (es)
CN (1) CN114980892A (es)
AU (1) AU2020346456A1 (es)
BR (1) BR112022004587A2 (es)
CA (1) CA3154321A1 (es)
CO (1) CO2022004596A2 (es)
MX (1) MX2022003018A (es)
WO (1) WO2021048822A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304437A (zh) * 2021-04-02 2023-02-01 日商武田藥品工業股份有限公司 食慾激素２受體促效劑對於手術後復原的用途
WO2024095158A1 (en) * 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
EP4119141A1 (en) * 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
HUE057696T2 (hu) 2016-02-04 2022-05-28 Takeda Pharmaceuticals Co Helyettesített piperidin vegyület és alkalmazása

Also Published As

Publication number Publication date
CA3154321A1 (en) 2021-03-18
BR112022004587A2 (pt) 2022-06-14
AU2020346456A1 (en) 2022-04-14
JP2022547711A (ja) 2022-11-15
KR20220062012A (ko) 2022-05-13
WO2021048822A1 (en) 2021-03-18
EP4028004A1 (en) 2022-07-20
CO2022004596A2 (es) 2022-08-30
CN114980892A (zh) 2022-08-30
US20220339143A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX2022003018A (es) Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
PE20130151A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2008011096A (es) Composicion para el tratamiento de superficies metalicas, metodo para el tratamiento de superficies metalicas y material metalico.
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
BR0212652A (pt) Composição para o tratamento de uma formação subterrânea, método de tratamento de uma formação subterrânea para aumentar a permeabilidade, e método de tratamento de um conjunto de escoramento numa fratura numa formação subterrânea para aumentar a sua permeabilidade
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
AU2021285747A8 (en) LPA receptor antagonists and uses thereof
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
MX2022012998A (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico.
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
PH12020551117A1 (en) Compositions for preventing or treating uveitis